Q5125 is the HCPCS code for: Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram. In 2024, 145 providers billed Q5125 3,670,982 times, with an estimated $1.4M paid by Medicare.
Q5125 is a Part B drug code: Medicare pays an ASP-based rate of $0.31 per 1 mcg (2026 Q3 ASP drug pricing file). Total payment per patient depends on the dose billed.
A billed "service" on this code is one 1 mcg unit, not one patient visit — that's why the service counts below run high.
What Medicare actually paid per service in 2024, on average: $0.38 (observed payment across all settings and modifiers — not a fee-schedule rate).
The top 5 billers nationally, ranked by 2024 Medicare service volume.
| # | Provider | Specialty | Location | Services | Est. Medicare paid |
|---|---|---|---|---|---|
| 1 | Sreecharan Reddy Mavuram, M.D | Medical Oncology | San Antonio, TX | 115,680 | $44K |
| 2 | Mark Fesen, MD | Medical Oncology | Great Bend, KS | 109,620 | $41K |
| 3 | Yunhui Hsiang, M.D., PHD | Hematology-Oncology | Ft Walton Beach, FL | 86,880 | $33K |
| 4 | Alberto Bessudo, M.D. | Hematology-Oncology | Encinitas, CA | 68,760 | $27K |
| 5 | Gibran Mahmud, M.D. | Hematology-Oncology | Centralia, IL | 67,620 | $25K |
Prospect 811 answers "what is this code, what does it pay, and who bills it?" for every billable code — then filters the answer to your exact territory, with phone numbers. $79/month, no contract, 14-day refund.
Start prospecting →